Aduro Clean Technologies Inc. (ADUR) has awarded a contract to Dutch engineering firm Ebert HERA for the preparation and coordination of civil and environmental permits at its first‑of‑a‑kind (FOAK) industrial site in the Chemelot industrial park, Netherlands. The contract covers the full permitting process required for the 10,000‑tonne‑per‑year Hydrochemolytic™ Technology plant, a key milestone on the path to commissioning the facility.
The award follows two recent public offerings that raised a combined $29.2 million—$9.2 million in June 2025 and $20 million in December 2025—providing the capital needed to advance permitting, construction, and early operations. The financing supports the project’s regulatory and construction phases, reducing the risk of schedule overruns and strengthening investor confidence in the company’s commercial timeline.
CEO Ofer Vicus said, “With the selection of Chemelot as the project site and initial offtake in place, we are now shifting focus to advancing the permitting work supported by local expertise as we move the FOAK project forward.” He added that “Selecting Chemelot marks a pivotal point in the scale‑up pathway we outlined last year. From the outset, our objective has been to transition from pilot‑scale validation to an industrial facility capable of operating under real‑world conditions, producing commercially relevant outputs, and supporting future growth.”
The permitting contract is a critical operational step that will enable Aduro to begin construction and, ultimately, generate revenue from its Hydrochemolytic™ Technology. By engaging Ebert HERA—an experienced partner within the Chemelot network—the company aims to streamline the complex Dutch regulatory process, mitigate potential delays, and keep the project on its projected two‑year timeline.
Ebert HERA’s role will include preparing and coordinating civil and environmental permit applications, managing regulatory engagement, and defining the permitting pathway for future capacity expansions. The partnership positions Aduro to accelerate the transition from pilot‑scale trials to full commercial operations, reducing execution risk and advancing the company’s strategic objective of delivering a scalable, circular chemistry solution.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.